Granules India reports 23 percent rise in Q3 profit
Granules, which also makes anti-inflammatory drug Ibuprofen, said 45.6 percent of its revenue came from finished dosages, the final ready-for-consumption product - its biggest segment.
Advertisement
Bengaluru: Pharmaceutical company Granules India Ltd, reported a 23 percent rise in third-quarter profit on Tuesday, propelled by strong demand for the painkiller drug Paracetamol.
Consolidated profit rose to 1.24 billion rupees ($15.22 million) for the three months ended Dec. 31, from 1.01 billion rupees a year earlier.
Consolidated revenue for the company rose nearly 15 percent to 11.46 billion rupees, "primarily driven by higher Paracetamol API sales in the US," the company said in an exchange filing.
"Opportunities in Paracetamol are likely to continue, and our geography expansion strategy in Europe is likely to yield higher turnover and EBITDA in future periods," Chairman Krishna Prasad Chigurupati said.
Granules, which also makes anti-inflammatory drug Ibuprofen, said 45.6 percent of its revenue came from finished dosages, the final ready-for-consumption product - its biggest segment.
Active pharmaceutical ingredients and pharmaceutical formulation intermediates contributed 35.8 percent and 18.6 percent, respectively, to the drug manufacturer's revenue.
Shares of the company climbed as much as 1.5 percent to 316.8 rupees, hitting a one-week high after the results. They declined 5.2 percent in 2022, compared with an 11.4 percent fall in the Nifty Pharma index.
Read also: Granules Pharma bags USFDA nod for ADHD drug Amphetamine Mixed Salts ER
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.